以岭药业(002603) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was CNY 1,827,460,855.67, representing a year-over-year increase of 3.78%[4] - Net profit attributable to shareholders reached CNY 331,869,647.18, a significant increase of 1,264.61% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was CNY 325,098,208.03, reflecting a year-over-year increase of 12,540.56%[4] - The basic earnings per share for the period was CNY 0.1986, marking an increase of 1,264.61% year-over-year[4] - Net profit for the current period is ¥996,674,335.90, an increase of 81.3% compared to ¥549,086,852.74 in the previous period[20] - Earnings per share (basic) increased to ¥0.5988 from ¥0.3321, reflecting a significant growth in profitability[21] Cash Flow - The operating cash flow net amount for the period was CNY 1,278,238,969.04, showing a substantial increase of 296.19%[10] - The company reported a significant increase in cash flow from operating activities, indicating improved operational efficiency[10] - Operating cash inflow for the current period reached ¥6,391,353,472.81, an increase of 14.1% from ¥5,600,361,187.31 in the previous period[22] - Net cash flow from operating activities was ¥1,278,238,969.04, significantly up from ¥322,629,831.08 in the prior period, marking a growth of 296.5%[22] - Cash inflow from financing activities was recorded at ¥1,047,716,733.33, with no cash received from new borrowings in the current period[23] - The ending cash and cash equivalents balance stood at ¥1,006,742,601.27, up from ¥861,239,443.20 in the previous period, reflecting an increase of 16.8%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,220,309,126.70, up 6.77% from the end of the previous year[5] - Total current assets increased to ¥5,539,592,346.04 from ¥4,334,951,809.12, representing a growth of approximately 27.7%[16] - Total assets increased to ¥14,220,309,126.70, up from ¥13,319,171,088.28, indicating a growth of 6.8%[18] - Total liabilities rose to ¥3,522,657,370.27, compared to ¥3,117,078,422.57, marking an increase of 13.0%[18] - The company's total equity attributable to shareholders increased to ¥10,703,839,026.93 from ¥10,223,487,732.27, a growth of 4.7%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 152,746[12] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of shares, totaling 526,775,963 shares[12] - The second-largest shareholder, Wu Xiangjun, holds 20.81% of shares, totaling 347,728,119 shares, with 260,796,089 shares pledged[12] Operational Metrics - The weighted average return on equity was 3.00%, an increase of 2.73% compared to the previous year[4] - The company has seen a 127.33% increase in receivables financing due to an increase in acceptance bills received during the reporting period[9] - Accounts receivable rose to ¥1,380,240,603.45 from ¥1,225,430,236.42, an increase of about 12.7%[16] - Inventory decreased to ¥1,685,040,655.83 from ¥1,746,380,345.14, a decline of approximately 3.5%[16] - Non-current assets include fixed assets valued at ¥5,833,684,973.51, down from ¥6,011,503,000.70[16] Other Financial Information - Research and development expenses for the current period were ¥544,012,861.24, slightly down from ¥571,912,835.78 in the previous period[19] - Deferred tax assets decreased to ¥307,687,897.66 from ¥365,836,675.85, a decline of 15.8%[18] - The company reported a significant increase in other income to ¥56,884,631.10 from ¥46,269,378.55, reflecting a growth of 22.5%[19] - Cash outflow for investment activities totaled ¥1,975,541,905.95, a decrease from ¥2,146,469,910.38 in the previous period[22] - Net cash flow from investment activities was -¥1,081,026,937.20, compared to -¥115,674.32 in the prior period, indicating a substantial increase in cash outflow[22] - The company received ¥15,814,249.80 in tax refunds, down from ¥39,663,227.37 in the previous period, indicating a decrease of 60.2%[22] - Cash received from the recovery of investments was ¥893,000,000.00, a decline from ¥2,133,000,000.00 in the previous period[22] Audit Information - The company did not conduct an audit for the third quarter financial report[24]